- Worldwide Net Revenue Increased 4% for the 2008 Third Quarter and
5% for the 2008 First Nine Months
- Third Quarter Revenue Growth in Pharmaceuticals Division Led by
Solid Growth of Enbrel +32%, Nutritionals +18% and Prevnar +13%
- Guidance for 2008 Full Year Diluted EPS, before Certain Significant
Items, Revised to a Range of $3.49 to $3.55
- Dividend to Stockholders Increased by 7.1%
MADISON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today reported results for the 2008 third quarter and first nine months ending September 30, 2008. Worldwide net revenue increased 4%, to $5.8 billion, for the 2008 third quarter and 5%, to $17.5 billion, for the first nine months of 2008. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 2% for the 2008 third quarter and increased 1% for the 2008 first nine months.
"Wyeth's results so far this year reflect the continued solid performance of our major growth engines - Enbrel, Prevnar and our Nutritionals franchise," said Bernard Poussot, Chairman, President and Chief Executive Officer. "For the first nine months of 2008, our revenues grew five percent despite the launch of Protonix generics last December. Wyeth has become a well diversified global biopharmaceutical company with 43 percent of its revenues represented by vaccines, biotechnology and nutritional products."
Product Highlights for the Third Quarter and First Nine Months of 2008
The following table presents worldwide net revenue from Wyeth's
principal products for the 2008 third quarter and first nine months,
together with the percentage changes from the comparable periods in th
Copyright©2008 PR Newswire.
All rights reserved